Guangzhou Imd Therapeutics Co. Ltd. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and/or bromodomain-containing protein 2 (BRD2) targeting moiety through a linker.